Shares of Alnylam Pharmaceuticals (ALNY) plunged Thursday after the biopharmaceutical company stopped development of its drug to treat hereditary conditions that can lead to nerve and heart damage. A late-stage study of the treatment determined that more patients died after receiving the drug than receiving a placebo. About half of Alnylam's market cap has vanished on the announcement

Employees of TheStreet are restricted from owning individual securities.